MAM
Mahindra Auto reports 10.3% decline in December sales
MUMBAI: Mahindra & Mahindra, a part of the $19.4 billion Mahindra Group, reported a 10.3 per cent drop in overall auto sales (passenger vehicles + commercial vehicles + exports) for the month of December 2020. The number of vehicles sold stood at 35,187 vehicles, down from 39,230 in December last year.
In the utility vehicles segment, Mahindra sold 16,050 vehicles in December 2020, compared to 15,225 vehicles in December 2019, registering a growth of five per cent.
The passenger vehicles segment (which includes SUVs, cars and vans) sold 16,182 vehicles in December 2020, a growth of three per cent over the same period last year.
M&M CEO automotive division Veejay Nakra said, “At Mahindra, we have witnessed a growth of five per cent in utility vehicles in the month of December. Our overall sales have been affected due to the continuing supply chain challenges related to the constantly changing global environment, more specifically the supply shortage of micro-processors (semiconductors) used in electronic control units (ECUs). Demand continues to remain strong even after the festive season and as we get into the new year.”
Exports for the month of December 2020 were at 2,210 vehicles.
MAM
Beacon Group appoints Dr Rajesh Patel as Group CEO
36-year healthcare veteran to lead Beacon Diagnostics, Vector Biotek, Biogeny.
MUMBAI: A new chief, a fresh diagnosis and a sharper prescription for growth. Beacon Group has appointed Dr Rajesh Patel as its Group Chief Executive Officer, effective April 1, 2026, signalling a decisive push to scale its presence in the diagnostics and IVD space. Patel steps into the role with 36 years of experience across the healthcare and diagnostics industry, bringing a career shaped by leadership roles spanning sales, marketing, business development and operational strategy. His mandate is both expansive and precise: to steer the group’s overall strategic direction while tightening coordination across its three core entities Beacon Diagnostics, Vector Biotek and Biogeny Diagnostics.
In practical terms, that means driving cross-company synergies, accelerating market expansion and strengthening organisational capability areas increasingly critical as diagnostic players compete for scale in a fragmented yet rapidly evolving healthcare ecosystem. The group is positioning itself to capture unmet demand across chain laboratories, key accounts and standalone labs, segments that remain underserved despite growing diagnostic needs.
The appointment comes at a time when the In Vitro Diagnostics (IVD) sector in India is entering a more competitive and innovation-led phase, with companies focusing not just on product pipelines but also on service delivery, integration and customer-centric models. Beacon’s leadership appears to be betting that Patel’s execution-focused approach can help translate ambition into operational momentum.
Welcoming the appointment, Chairman Dr D K Joshi described Patel’s induction as a strategic move aligned with the group’s long-term vision, emphasising the role of leadership depth in navigating the next phase of growth.
For Beacon Group, the message is clear, in a sector where precision matters, leadership is the new differentiator—and this appointment is intended to set the tone for what comes next.
